Oragenics Stock Performance
| OGEN Stock | USD 0.87 0.03 3.57% |
The company holds a Beta of 1.15, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oragenics will likely underperform. At this point, Oragenics has a negative expected return of -0.64%. Please make sure to check Oragenics' total risk alpha, as well as the relationship between the skewness and day median price , to decide if Oragenics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Oragenics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in February 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Oragenics | Build AI portfolio with Oragenics Stock |
Oragenics Relative Risk vs. Return Landscape
If you would invest 137.00 in Oragenics on October 7, 2025 and sell it today you would lose (50.00) from holding Oragenics or give up 36.5% of portfolio value over 90 days. Oragenics is currently does not generate positive expected returns and assumes 4.0708% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Oragenics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oragenics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oragenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oragenics, and traders can use it to determine the average amount a Oragenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1564
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OGEN |
Based on monthly moving average Oragenics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oragenics by adding Oragenics to a well-diversified portfolio.
Oragenics Fundamentals Growth
Oragenics Stock prices reflect investors' perceptions of the future prospects and financial health of Oragenics, and Oragenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oragenics Stock performance.
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | (7.53 M) | ||||
| Shares Outstanding | 4.17 M | ||||
| Price To Earning | (2.28) X | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 89.28 X | ||||
| EBITDA | (10.54 M) | ||||
| Cash And Equivalents | 17.87 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 328.53 K | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 2.38 X | ||||
| Cash Flow From Operations | (8.6 M) | ||||
| Earnings Per Share | 48.21 X | ||||
| Total Asset | 1.47 M | ||||
| Retained Earnings | (216.79 M) | ||||
| Current Asset | 5.64 M | ||||
| Current Liabilities | 1.05 M | ||||
About Oragenics Performance
By examining Oragenics' fundamental ratios, stakeholders can obtain critical insights into Oragenics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Oragenics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. Oragenics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.Things to note about Oragenics performance evaluation
Checking the ongoing alerts about Oragenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oragenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oragenics generated a negative expected return over the last 90 days | |
| Oragenics has some characteristics of a very speculative penny stock | |
| Oragenics has high historical volatility and very poor performance | |
| Net Loss for the year was (10.57 M) with loss before overhead, payroll, taxes, and interest of (3.39 M). | |
| Oragenics currently holds about 17.87 M in cash with (8.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. | |
| Oragenics has a poor financial position based on the latest SEC disclosures |
- Analyzing Oragenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oragenics' stock is overvalued or undervalued compared to its peers.
- Examining Oragenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oragenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oragenics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oragenics' stock. These opinions can provide insight into Oragenics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.